JP2017523170A - 非糖尿病の雌性哺乳動物において生殖能力及び正常な妊孕力を刺激するための及び生殖補助医療の有効性を改善させるための、不妊症の治療に使用されるタングステン(vi)塩 - Google Patents
非糖尿病の雌性哺乳動物において生殖能力及び正常な妊孕力を刺激するための及び生殖補助医療の有効性を改善させるための、不妊症の治療に使用されるタングステン(vi)塩 Download PDFInfo
- Publication number
- JP2017523170A JP2017523170A JP2017502966A JP2017502966A JP2017523170A JP 2017523170 A JP2017523170 A JP 2017523170A JP 2017502966 A JP2017502966 A JP 2017502966A JP 2017502966 A JP2017502966 A JP 2017502966A JP 2017523170 A JP2017523170 A JP 2017523170A
- Authority
- JP
- Japan
- Prior art keywords
- tungsten
- fertility
- salt
- composition
- mammals
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000124008 Mammalia Species 0.000 title claims abstract description 67
- 230000035558 fertility Effects 0.000 title claims abstract description 67
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 58
- FZFRVZDLZISPFJ-UHFFFAOYSA-N tungsten(6+) Chemical class [W+6] FZFRVZDLZISPFJ-UHFFFAOYSA-N 0.000 title claims abstract description 51
- 208000000509 infertility Diseases 0.000 title claims abstract description 36
- 230000036512 infertility Effects 0.000 title claims abstract description 35
- 231100000535 infertility Toxicity 0.000 title claims abstract description 34
- 238000011282 treatment Methods 0.000 title abstract description 30
- 239000000203 mixture Substances 0.000 claims abstract description 52
- 238000000034 method Methods 0.000 claims abstract description 24
- 239000003814 drug Substances 0.000 claims abstract description 11
- 230000001850 reproductive effect Effects 0.000 claims abstract description 7
- 239000012453 solvate Substances 0.000 claims description 19
- 230000000694 effects Effects 0.000 claims description 16
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 15
- -1 tungsten (VI) anion Chemical class 0.000 claims description 15
- 235000013305 food Nutrition 0.000 claims description 14
- 210000001161 mammalian embryo Anatomy 0.000 claims description 14
- 230000016087 ovulation Effects 0.000 claims description 14
- 150000001768 cations Chemical class 0.000 claims description 13
- 235000015872 dietary supplement Nutrition 0.000 claims description 13
- 238000002513 implantation Methods 0.000 claims description 12
- 230000037396 body weight Effects 0.000 claims description 10
- 230000001737 promoting effect Effects 0.000 claims description 10
- 210000000287 oocyte Anatomy 0.000 claims description 8
- 239000000243 solution Substances 0.000 claims description 8
- 229910052721 tungsten Inorganic materials 0.000 claims description 8
- 239000010937 tungsten Substances 0.000 claims description 8
- 235000013361 beverage Nutrition 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 208000035475 disorder Diseases 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 6
- 239000011734 sodium Substances 0.000 claims description 6
- 239000011701 zinc Substances 0.000 claims description 6
- 229910052725 zinc Inorganic materials 0.000 claims description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 5
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 229910052708 sodium Inorganic materials 0.000 claims description 5
- 239000008247 solid mixture Substances 0.000 claims description 5
- 208000030814 Eating disease Diseases 0.000 claims description 4
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 4
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 4
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 4
- 239000011575 calcium Substances 0.000 claims description 4
- 150000004683 dihydrates Chemical class 0.000 claims description 4
- 235000014632 disordered eating Nutrition 0.000 claims description 4
- 239000007938 effervescent tablet Substances 0.000 claims description 4
- 239000005720 sucrose Substances 0.000 claims description 4
- 239000013589 supplement Substances 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 3
- 208000015943 Coeliac disease Diseases 0.000 claims description 3
- 201000009273 Endometriosis Diseases 0.000 claims description 3
- 206010016654 Fibrosis Diseases 0.000 claims description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 3
- 229910052783 alkali metal Inorganic materials 0.000 claims description 3
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims description 3
- 150000001450 anions Chemical class 0.000 claims description 3
- 229910052791 calcium Inorganic materials 0.000 claims description 3
- 208000020832 chronic kidney disease Diseases 0.000 claims description 3
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims description 3
- 230000007882 cirrhosis Effects 0.000 claims description 3
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 208000003532 hypothyroidism Diseases 0.000 claims description 3
- 230000002989 hypothyroidism Effects 0.000 claims description 3
- 229910052749 magnesium Inorganic materials 0.000 claims description 3
- 239000011777 magnesium Substances 0.000 claims description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims description 3
- 229910052700 potassium Inorganic materials 0.000 claims description 3
- 239000011591 potassium Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 239000006188 syrup Substances 0.000 claims description 3
- 235000020357 syrup Nutrition 0.000 claims description 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 3
- 235000012431 wafers Nutrition 0.000 claims description 3
- 208000032841 Bulimia Diseases 0.000 claims description 2
- 206010006550 Bulimia nervosa Diseases 0.000 claims description 2
- 239000007911 effervescent powder Substances 0.000 claims description 2
- 150000002500 ions Chemical group 0.000 claims description 2
- 208000022531 anorexia Diseases 0.000 claims 1
- 206010061428 decreased appetite Diseases 0.000 claims 1
- 230000002267 hypothalamic effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000000926 neurological effect Effects 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 230000001817 pituitary effect Effects 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 description 56
- 102100025092 Insulin receptor substrate 2 Human genes 0.000 description 29
- 101001077600 Homo sapiens Insulin receptor substrate 2 Proteins 0.000 description 26
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 18
- 230000035935 pregnancy Effects 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 17
- 230000012173 estrus Effects 0.000 description 17
- XMVONEAAOPAGAO-UHFFFAOYSA-N sodium tungstate Chemical compound [Na+].[Na+].[O-][W]([O-])(=O)=O XMVONEAAOPAGAO-UHFFFAOYSA-N 0.000 description 14
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 12
- 206010022489 Insulin Resistance Diseases 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 12
- 239000008103 glucose Substances 0.000 description 12
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 238000010171 animal model Methods 0.000 description 10
- 102000004877 Insulin Human genes 0.000 description 9
- 108090001061 Insulin Proteins 0.000 description 9
- 229940125396 insulin Drugs 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 230000027758 ovulation cycle Effects 0.000 description 8
- 238000011084 recovery Methods 0.000 description 8
- 235000008429 bread Nutrition 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 150000003657 tungsten Chemical class 0.000 description 7
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 230000004720 fertilization Effects 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 5
- 102000016267 Leptin Human genes 0.000 description 5
- 108010092277 Leptin Proteins 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 210000002257 embryonic structure Anatomy 0.000 description 5
- 230000002357 endometrial effect Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 230000007775 late Effects 0.000 description 5
- 229940039781 leptin Drugs 0.000 description 5
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 5
- 239000000314 lubricant Substances 0.000 description 5
- QWMFKVNJIYNWII-UHFFFAOYSA-N 5-bromo-2-(2,5-dimethylpyrrol-1-yl)pyridine Chemical compound CC1=CC=C(C)N1C1=CC=C(Br)C=N1 QWMFKVNJIYNWII-UHFFFAOYSA-N 0.000 description 4
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000011835 investigation Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- PBYZMCDFOULPGH-UHFFFAOYSA-N tungstate Chemical compound [O-][W]([O-])(=O)=O PBYZMCDFOULPGH-UHFFFAOYSA-N 0.000 description 4
- 101710201820 Insulin receptor substrate 2 Proteins 0.000 description 3
- 244000269722 Thea sinensis Species 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 239000003651 drinking water Substances 0.000 description 3
- 235000020188 drinking water Nutrition 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 230000004153 glucose metabolism Effects 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 208000021267 infertility disease Diseases 0.000 description 3
- 230000009027 insemination Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000001019 normoglycemic effect Effects 0.000 description 3
- 235000019533 nutritive sweetener Nutrition 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 230000002085 persistent effect Effects 0.000 description 3
- YCGBUPXEBUFYFV-UHFFFAOYSA-N withaferin A Natural products CC(C1CC(=C(CO)C(=O)O1)C)C2CCC3C4CC5OC56C(O)C=CC(O)C6(C)C4CCC23C YCGBUPXEBUFYFV-UHFFFAOYSA-N 0.000 description 3
- DBRXOUCRJQVYJQ-CKNDUULBSA-N withaferin A Chemical compound C([C@@H]1[C@H]([C@@H]2[C@]3(CC[C@@H]4[C@@]5(C)C(=O)C=C[C@H](O)[C@@]65O[C@@H]6C[C@H]4[C@@H]3CC2)C)C)C(C)=C(CO)C(=O)O1 DBRXOUCRJQVYJQ-CKNDUULBSA-N 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- PYTMYKVIJXPNBD-OQKDUQJOSA-N 2-[4-[(z)-2-chloro-1,2-diphenylethenyl]phenoxy]-n,n-diethylethanamine;hydron;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(/Cl)C1=CC=CC=C1 PYTMYKVIJXPNBD-OQKDUQJOSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 206010061452 Complication of pregnancy Diseases 0.000 description 2
- 244000281702 Dioscorea villosa Species 0.000 description 2
- 235000000504 Dioscorea villosa Nutrition 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 208000007984 Female Infertility Diseases 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010021928 Infertility female Diseases 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 206010033307 Overweight Diseases 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 244000098338 Triticum aestivum Species 0.000 description 2
- 244000274883 Urtica dioica Species 0.000 description 2
- 235000009108 Urtica dioica Nutrition 0.000 description 2
- 235000001667 Vitex agnus castus Nutrition 0.000 description 2
- 244000063464 Vitex agnus-castus Species 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 2
- 235000020244 animal milk Nutrition 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229940046989 clomiphene citrate Drugs 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000003433 contraceptive agent Substances 0.000 description 2
- 230000002254 contraceptive effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 235000015071 dressings Nutrition 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 230000032692 embryo implantation Effects 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000019439 energy homeostasis Effects 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- ZINJLDJMHCUBIP-UHFFFAOYSA-N ethametsulfuron-methyl Chemical compound CCOC1=NC(NC)=NC(NC(=O)NS(=O)(=O)C=2C(=CC=CC=2)C(=O)OC)=N1 ZINJLDJMHCUBIP-UHFFFAOYSA-N 0.000 description 2
- 210000000416 exudates and transudate Anatomy 0.000 description 2
- 231100000502 fertility decrease Toxicity 0.000 description 2
- 238000007667 floating Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 230000008217 follicular development Effects 0.000 description 2
- 235000011194 food seasoning agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 208000031424 hyperprolactinemia Diseases 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 235000008960 ketchup Nutrition 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000013011 mating Effects 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000004681 ovum Anatomy 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 208000012113 pregnancy disease Diseases 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 235000014214 soft drink Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 235000000891 standard diet Nutrition 0.000 description 2
- 229960001052 streptozocin Drugs 0.000 description 2
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- 210000000143 trophectoderm cell Anatomy 0.000 description 2
- 210000002993 trophoblast Anatomy 0.000 description 2
- 239000000052 vinegar Substances 0.000 description 2
- 235000021419 vinegar Nutrition 0.000 description 2
- 230000002747 voluntary effect Effects 0.000 description 2
- 206010000599 Acromegaly Diseases 0.000 description 1
- 241000906543 Actaea racemosa Species 0.000 description 1
- 241000411852 Aletris farinosa Species 0.000 description 1
- 241000382455 Angelica sinensis Species 0.000 description 1
- 208000000103 Anorexia Nervosa Diseases 0.000 description 1
- 206010002650 Anorexia nervosa and bulimia Diseases 0.000 description 1
- 201000005670 Anovulation Diseases 0.000 description 1
- 206010002659 Anovulatory cycle Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 235000007320 Avena fatua Nutrition 0.000 description 1
- 244000075850 Avena orientalis Species 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 241001647031 Avena sterilis Species 0.000 description 1
- 235000004535 Avena sterilis Nutrition 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 244000018436 Coriandrum sativum Species 0.000 description 1
- 235000002787 Coriandrum sativum Nutrition 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 201000005948 Donohue syndrome Diseases 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 208000033206 Early menarche Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000030271 Fetal Nutrition disease Diseases 0.000 description 1
- 206010016862 Foetal malnutrition Diseases 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 101100287084 Homo sapiens IRS2 gene Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 201000002980 Hyperparathyroidism Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 244000017020 Ipomoea batatas Species 0.000 description 1
- 235000002678 Ipomoea batatas Nutrition 0.000 description 1
- 101150029468 Irs2 gene Proteins 0.000 description 1
- 240000005183 Lantana involucrata Species 0.000 description 1
- 235000013628 Lantana involucrata Nutrition 0.000 description 1
- 241001425930 Latina Species 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 235000006677 Monarda citriodora ssp. austromontana Nutrition 0.000 description 1
- 208000034702 Multiple pregnancies Diseases 0.000 description 1
- 101100287085 Mus musculus Irs2 gene Proteins 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 235000010676 Ocimum basilicum Nutrition 0.000 description 1
- 240000007926 Ocimum gratissimum Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000011707 Ovulation disease Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 240000009164 Petroselinum crispum Species 0.000 description 1
- 201000010769 Prader-Willi syndrome Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 240000001949 Taraxacum officinale Species 0.000 description 1
- 235000006754 Taraxacum officinale Nutrition 0.000 description 1
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 description 1
- 208000037063 Thinness Diseases 0.000 description 1
- 235000015724 Trifolium pratense Nutrition 0.000 description 1
- 240000000143 Turnera diffusa Species 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- HFRYTYJESLXSNO-UHFFFAOYSA-N [Na+].[W+6] Chemical group [Na+].[W+6] HFRYTYJESLXSNO-UHFFFAOYSA-N 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 231100000552 anovulation Toxicity 0.000 description 1
- 230000002513 anti-ovulatory effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008122 artificial sweetener Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- FQOGPKGKZVXZCZ-UHFFFAOYSA-L calcium;2-hydroxypropane-1,2,3-tricarboxylic acid;carbonate Chemical compound [Ca+2].[O-]C([O-])=O.OC(=O)CC(O)(C(O)=O)CC(O)=O FQOGPKGKZVXZCZ-UHFFFAOYSA-L 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 150000001767 cationic compounds Chemical class 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 231100001041 changes in fertility Toxicity 0.000 description 1
- 235000009347 chasteberry Nutrition 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 235000005301 cimicifuga racemosa Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000012489 doughnuts Nutrition 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000003981 ectoderm Anatomy 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000005168 endometrial cell Anatomy 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 210000004996 female reproductive system Anatomy 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 230000014101 glucose homeostasis Effects 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 235000015092 herbal tea Nutrition 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910001411 inorganic cation Inorganic materials 0.000 description 1
- 150000002505 iron Chemical class 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 235000015141 kefir Nutrition 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000020166 milkshake Nutrition 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 235000020786 mineral supplement Nutrition 0.000 description 1
- 229940029985 mineral supplement Drugs 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 235000012459 muffins Nutrition 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 208000001797 obstructive sleep apnea Diseases 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- 150000002892 organic cations Chemical class 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 235000011197 perejil Nutrition 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 235000013526 red clover Nutrition 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000014438 salad dressings Nutrition 0.000 description 1
- 230000000276 sedentary effect Effects 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 235000021055 solid food Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 230000019100 sperm motility Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003451 thiazide diuretic agent Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000021404 traditional food Nutrition 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 235000004952 turnera diffusa Nutrition 0.000 description 1
- 206010048828 underweight Diseases 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 235000015192 vegetable juice Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019195 vitamin supplement Nutrition 0.000 description 1
- 235000008939 whole milk Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01G—COMPOUNDS CONTAINING METALS NOT COVERED BY SUBCLASSES C01D OR C01F
- C01G41/00—Compounds of tungsten
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01G—COMPOUNDS CONTAINING METALS NOT COVERED BY SUBCLASSES C01D OR C01F
- C01G41/00—Compounds of tungsten
- C01G41/02—Oxides; Hydroxides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Powder Metallurgy (AREA)
- Fodder In General (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Electroplating And Plating Baths Therefor (AREA)
- Inorganic Insulating Materials (AREA)
- Radiation-Therapy Devices (AREA)
Abstract
Description
*低受胎状態では:定期的な、避妊を行わない性交を行った12カ月の間に妊娠する;及び、
*不妊症状態では:定期的な、避妊を行わない性交を行った12カ月を過ぎて妊娠する。本明細書において、排卵を回復及び/促進させ、卵母細胞及び胚の品質を改善させ、子宮壁への接合体の着床を増大させ、多嚢胞性卵巣症候群、メタボリックシンドローム、高プロラクチン血症、子宮内膜症、甲状腺機能低下症、多発性硬化症、関節リウマチ、全身性エリテマトーデス、肝硬変、関節リウマチ、セリアック病、慢性腎不全、特発性の原因及び摂食障害、例えば神経性無食欲症及び多食症を含む、視床下部−下垂体−卵巣軸の障害を調節する必要を含む。
正常な妊孕力及び生殖能力を促すためのタングステン(VI)塩の活性を求めるために使用されたマウスモデルは、Irs2遺伝子ノックアウトマウスであるIRS2−/−である[Burks et. al., "IRS-2 pathways integrate female reproduction and energy homeostasis", Nature, 2000, vol. 407, pp. 377-382]。Irs2遺伝子の欠失が、生殖能力及び糖質代謝に関連する明らかな性的二型性を示すと解釈されている。
A.動物
6週齢〜8週齢の10匹のIRS2−/−雌性マウス。
6週齢〜8週齢の6匹の「野生型」(IRS2wt)雄性マウス。
前処理段階
順応期間の後、IRS2−/−雌性マウスを1つのケージ当たり4匹〜6匹のマウス群で飼育した。前処理段階(2週間)の間、動物にタングステン酸塩不含飲用水を投与した。
前処理段階(治療0日目)後から動物を屠殺する4週間前まで、蒸留水中、タングステン酸ナトリウム二水和物(Carlo Erbaにより販売される)の2mg/ml溶液を用いた飲用水(任意)においてタングステン酸ナトリウムを投与した。マウスにより摂取されたタングステン酸ナトリウムの1日用量は体重1kg当たり約180mgであった。
治療の最初の3週間の後、IRS2−/−雌性マウスをIRS2wt雄性マウスと継続的につがいでケージにおいて飼育した。
この期間の後、雌性マウスを屠殺し、妊娠の兆候を求めて生検を行った。
排卵調査の結果
前処理期間中及び治療の最初の3週間の間、−8日目、−5日目、−2日目、−1日目、7日目、8日目、14日目、15日目及び22日目に無作為に選択した6匹の雌性マウスにおいて膣垢検査を行い、それらのマウスの発情周期の段階を求めた。
50体積%アルコール中に10回浸漬、
ハリスヘマトキシリン溶液中に3分間浸漬、
流水ですすぐ、
酸アルコール(1%塩酸)中に10回浸漬、
流水ですすぐ、
95体積%アルコール中に10回浸漬、
OG−6溶液中に30秒間浸漬、
96体積%アルコール中に10回浸漬、
エオシン溶液中に1分間浸漬、
96体積%アルコール中に10回浸漬、
86体積%アルコール中に10回浸漬、及び、
キシロール中に10回浸漬。
B欄の方法の交配期間の後、雌性マウスを屠殺し、妊娠の兆候を求めて生検を行った。
A.動物
6週齢〜8週齢の6匹のIRS2−/−雌性マウス。
治療段階
順応期間の後、前処理段階(治療0日目)後に、及び12日間に亘り、蒸留水中、タングステン酸ナトリウム二水和物(Carlo Erbaにより販売される)の2mg/ml溶液を用いた飲用水(任意)においてタングステン酸ナトリウムを投与した。
治療期間の0日目、2日目、5日目、7日目、9日目及び12日目に体重をモニターし、上述の日の各々において6時間の絶食の後、尾静脈からの採血及びグルコースセンサー(ドイツ国マンハイムのRocheのAccuTrendグルコースセンサー)により血中グルコースを求めた。
A.モデル
HEC1−A子宮内膜細胞株及びJEG−3栄養外胚葉細胞株から作製された「in vitro」のヒト−ヒト胚の接着モデルを使用し、子宮内膜の受容性に対するタングステン酸ナトリウムの影響を求めた。
細胞株は、子宮内膜の胚の接着実験を行うために市販のものが購入された(米国培養細胞系統保存機関(ATCC);米国メリーランド州ロックビル)。これらの細胞を解凍し、十分な細胞を得るため4回増殖させ、全てのアッセイを行った。
得られた結果を表5に挙げる。より高い割合の胚の接着は、HEC−1A株をタングステン酸ナトリウムで処理していないものに対してタングステン酸ナトリウムで処理した条件下において観察された。陰性対照(C−)である、WithaferinAで処理した細胞において接着は一切観察されなかった。
本発明による食品組成物を以下の説明のように調製する。組成物は、本発明の範囲を限定するものとして解釈されるものではない。
タングステン塩を多く含むサラダドレッシングを調製する。25mgのNa2WO4(100mg/kg)を、250グラムの市販のドレッシングに添加し、それを30分間機械により撹拌する。
タングステン塩を多く含むケチャップタイプサルサを調製する。そのため170mgのCa2WO4を、200グラムの市販のケチャップに添加し、それを1時間機械により撹拌する。
タングステン塩を多く含むミルクを調製する。そのため1kgの全牛乳を用意し、150mgのZnWO4を添加し、それを20分間機械により撹拌する。摂取直前にパッケージを振ることが推奨される。
タングステン塩を多く含むフルーツジュースを調製する。500mgのMgWO4を1kgの市販のジュースに添加し、それを10分間機械により撹拌する。摂取直前にパッケージを振ることが推奨される。
以下の組成物でコーティングした錠剤を調製する:
PH200微結晶セルロース(希釈剤/滑沢剤) 250.00mg
コロイド状無水シリカ(滑沢剤/吸着剤) 3.00mg
ステアリン酸マグネシウム(潤滑剤) 5.00mg
タルク(潤滑剤) 7.00mg
オパドライ(商標)ホワイト(オパドライ(商標)及び−1−7000ホワイト)(*)(コーティングフィルム) 8.00mg
タングステン酸ナトリウム二水和物 200.00mg
(*)ヒドロキシプロピルメチルセルロース、ポリエチレングリコール6000及び酸化チタン(E−171)の混合物
以下の組成物を含む発泡性錠剤を調製する:
ソルビトール、アスパルテーム、スクロース及びキシリトール(甘味剤) 10mg当たり0.025mg
炭酸カルシウム 10mg当たり0.350mg
クエン酸(酸味料) 10mg当たり0.650mg
酸性炭酸ナトリウム(pH調整剤) 10mg当たり0.350mg
オレンジ香味料 10mg当たり0.25mg
タングステン塩
以下の組成物を含むゼラチンカプセルを調製する:
ニフェジピン 6mg
キサンタンガム 5mg
オレンジ香味料 0.3mg
クエン酸 0.4mg
ゲルシア(Gelucire)44/14 90mg
PH10微結晶セルロース(希釈剤) 92.00mg/カプセル
タングステン酸ナトリウム二水和物 100.00mg/カプセル
Claims (23)
- 非糖尿病の雌性哺乳動物において不妊症を治療するために、非糖尿病の雌性哺乳動物において正常な妊孕力及び生殖能力を促すために、又は哺乳動物において生殖補助医療の効果を改善するために使用されるタングステン(VI)塩又はその溶媒和物。
- 前記哺乳動物がヒトである、請求項1に記載のタングステン(VI)塩。
- 雌性哺乳動物の体重1kg当たり0.001mg〜1000mgのタングステン(VI)塩の1日用量にて投与する、請求項1又は2に記載のタングステン(VI)塩。
- タングステン(VI)アニオン及び薬学的、獣医学的又は栄養学的に許容可能なカチオンを含む、請求項1〜3のいずれか一項に記載のタングステン(VI)塩。
- 前記カチオンがアルカリ金属カチオン又はアルカリ土類金属カチオンである、請求項1〜4のいずれか一項に記載のタングステン(VI)塩。
- 前記カチオンがナトリウム、カリウム、マグネシウム、カルシウム及び亜鉛からなる群から選択されることを特徴とする、請求項1〜5のいずれか一項に記載のタングステン(VI)塩。
- 前記カチオンがナトリウムであることを特徴とする、請求項6に記載のタングステン(VI)塩。
- 前記カチオンが亜鉛である、請求項6に記載のタングステン(VI)塩。
- 前記タングステン(VI)アニオンがWO4 2−イオン、HWO4 −イオン、W2O7 2−イオン及びHW2O7 −イオンから選択されることを特徴とする、請求項1〜8のいずれか一項に記載のタングステン(VI)塩。
- 前記アニオンがWO4 2−であることを特徴とする、請求項9に記載のタングステン(VI)塩。
- 前記溶媒和物が二水和物である、請求項1〜10のいずれか一項に記載のタングステン(VI)塩。
- 前記非糖尿病の雌性哺乳動物が排卵を回復及び/又は促進させ、卵母細胞又は胚の品質を改善させ、子宮壁への接合体着床を増大させ、多嚢胞性卵巣症候群、メタボリックシンドローム、高プロラクチン血症、子宮内膜症、甲状腺機能低下症、多発性硬化症、関節リウマチ、全身性エリテマトーデス、肝硬変、関節リウマチ、セリアック病、慢性腎不全、特発性の原因及び摂食障害、例えば神経性無食欲症及び多食症を含む視床下部下垂体軸の障害を調節することを必要とする哺乳動物の群から選択される、請求項1〜11のいずれか一項に記載のタングステン(VI)塩。
- 非糖尿病の雌性哺乳動物において不妊症を治療するための、非糖尿病の雌性哺乳動物において正常な妊孕力及び生殖能力を促すための、又は哺乳動物に適用された生殖補助医療の効果を改善するための、100mg/kg以上の濃度の請求項1〜12のいずれか一項に記載のタングステン(VI)塩又はその溶媒和物と少なくとも1つの薬学的、獣医学的又は栄養学的に許容可能な賦形剤又はベヒクルとを含む組成物。
- 前記賦形剤又はベヒクルが薬学的に又は獣医学的に許容可能であり、前記組成物が非糖尿病の雌性哺乳動物において不妊症を治療するための医薬組成物であることを特徴とする、請求項13に記載の組成物。
- 前記賦形剤又はベヒクルが薬学的又は獣医学的に許容可能であり、前記組成物が哺乳動物に適用した生殖補助医療の効果を増大させるための医薬組成物であることを特徴とする、請求項13に記載の組成物。
- ピル、錠剤、トローチ、カプセル、粉末、ウエハー、発泡性粉末若しくは錠剤、溶液、懸濁液、シロップ又は顆粒の形態であることを特徴とする、請求項14又は15に記載の組成物。
- 非糖尿病の雌性哺乳動物において正常な妊孕力及び生殖能力を促すための食品組成物であることを特徴とする、請求項13に記載の組成物。
- 液状組成物又は飲料であることを特徴とする、請求項17に記載の組成物。
- 固形組成物であることを特徴とする、請求項17に記載の組成物。
- 前記食品組成物が栄養補助剤又は補足物であることを特徴とする、請求項17に記載の組成物。
- スクロースを含むことを特徴とする、請求項13〜20のいずれか一項に記載の組成物。
- 非糖尿病の雌性哺乳動物において不妊症を治療するための、非糖尿病の雌性哺乳動物において正常な妊孕力及び生殖能力を促すための、又は哺乳動物に適用した生殖補助医療の効果を増大させるための、医薬品の製造における請求項1〜12のいずれか一項に記載のタングステン(VI)塩又はその溶媒和物の使用。
- 不妊症を治療するための、非糖尿病の雌性哺乳動物において正常な妊孕力及び生殖能力を促すための、又は哺乳動物に適用した生殖補助医療の効果を増大させるための方法であって、治療有効量の請求項1〜12のいずれか一項に記載のタングステン(VI)塩又はその溶媒和物を投与することを含む、方法。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/ES2014/070586 WO2016012632A1 (es) | 2014-07-21 | 2014-07-21 | Sales de tungsteno (vi) para su uso en el tratamiento de la infertilidad, para favorecer la fertilidad y la reproducción normal en un mamífero hembra no diabético, así como para mejorar la eficacia de las técnicas de reproducción asistida |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2017523170A true JP2017523170A (ja) | 2017-08-17 |
JP6534439B2 JP6534439B2 (ja) | 2019-06-26 |
Family
ID=55162540
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017502966A Active JP6534439B2 (ja) | 2014-07-21 | 2014-07-21 | 非糖尿病の雌性哺乳動物において生殖能力及び正常な妊孕力を刺激するための及び生殖補助医療の有効性を改善させるための、不妊症の治療に使用されるタングステン(vi)塩 |
Country Status (27)
Country | Link |
---|---|
US (1) | US10376540B2 (ja) |
EP (1) | EP3173382B1 (ja) |
JP (1) | JP6534439B2 (ja) |
KR (1) | KR102282865B1 (ja) |
CN (1) | CN106715332B (ja) |
AR (1) | AR101252A1 (ja) |
AU (1) | AU2014401750B2 (ja) |
BR (1) | BR112017001287A2 (ja) |
CA (1) | CA2955914C (ja) |
DK (1) | DK3173382T3 (ja) |
ES (1) | ES2940465T3 (ja) |
FI (1) | FI3173382T3 (ja) |
HR (1) | HRP20230223T1 (ja) |
HU (1) | HUE061726T2 (ja) |
IL (1) | IL250212B (ja) |
LT (1) | LT3173382T (ja) |
MX (1) | MX2017000927A (ja) |
PL (1) | PL3173382T3 (ja) |
PT (1) | PT3173382T (ja) |
RS (1) | RS64025B1 (ja) |
RU (1) | RU2679623C2 (ja) |
SG (1) | SG11201700485VA (ja) |
SI (1) | SI3173382T1 (ja) |
TW (1) | TWI709407B (ja) |
UY (1) | UY36222A (ja) |
WO (1) | WO2016012632A1 (ja) |
ZA (1) | ZA201701241B (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4368577A1 (en) | 2022-11-08 | 2024-05-15 | Oxolife, S.L. | Process for the preparation of tungsten (vi) salt hydrates |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6045721B2 (ja) * | 2013-01-22 | 2016-12-14 | オキソライフ エセ.エレ. | 非糖尿病の哺乳動物における雌性不妊症の治療のためのタングステン(vi)塩の使用 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2245374B1 (ja) * | 1973-07-27 | 1977-02-25 | Anvar | |
US4328134A (en) * | 1980-05-06 | 1982-05-04 | Schally Andrew Victor | Anorexigenic peptides |
ES2108642B1 (es) | 1995-07-26 | 1998-08-16 | Quimica Farm Bayer Sa | Composiciones de tungsteno (vi) para el tratamiento oral de la diabetes mellitus. |
RU2202314C2 (ru) * | 2001-04-11 | 2003-04-20 | Алексей Иванович Ступко | Способ подготовки пациентки к искусственному оплодотворению |
ES2187276B1 (es) * | 2001-05-16 | 2004-08-01 | Quimica Farmaceutica Bayer,S.A. | Composiciones orales para el tratamiento de humanos obesos y no diabeticos. |
CA2500897A1 (en) * | 2002-10-02 | 2004-04-15 | Yeda Research And Development Co. Ltd. | Long-acting gonadotropin-releasing hormone analogs and methods of use thereof |
EP1523985B1 (en) * | 2003-10-17 | 2010-03-10 | Oy Neurofood Ab | Non-radioactive strontium agent for treating cancer |
EP2395112B1 (en) * | 2003-12-31 | 2017-02-15 | The Penn State Research Foundation | Methods for predicting and overcoming resistance to chemotherapy in ovarian cancer and for predicting colon cancer occurrence |
US20090081177A1 (en) * | 2005-07-05 | 2009-03-26 | Fertility Technologies Pty Ltd | Methods and compositions for improving pregnancy outcome |
EP1972342A4 (en) * | 2005-07-29 | 2011-01-12 | Univ Barcelona | PHARMACEUTICAL TREATED SALT (VI) COMPOSITIONS FOR THE TREATMENT OF NEURODEEGENERATIVE DISORDERS, IN PARTICULAR ALZHEIMER DISEASE AND SCHIZOPHRENIA |
US20060100154A1 (en) * | 2005-10-13 | 2006-05-11 | Yeda Research And Development Co | Long-acting gonadotropin-releasing hormone analogs and methods of use thereof |
CN105664141A (zh) * | 2006-10-18 | 2016-06-15 | 派利尼斯有限公司 | 脱氧核糖核酸酶在制备用于治疗男性低生育力的药物中的应用 |
ES2551828B1 (es) * | 2014-05-21 | 2016-09-12 | Oxolife S.L. | Composiciones alimentarias que comprenden sales de tungsteno (VI) |
-
2014
- 2014-07-21 US US15/327,292 patent/US10376540B2/en active Active
- 2014-07-21 RU RU2017105257A patent/RU2679623C2/ru active
- 2014-07-21 LT LTEPPCT/ES2014/070586T patent/LT3173382T/lt unknown
- 2014-07-21 MX MX2017000927A patent/MX2017000927A/es unknown
- 2014-07-21 SI SI201432020T patent/SI3173382T1/sl unknown
- 2014-07-21 CA CA2955914A patent/CA2955914C/en active Active
- 2014-07-21 PT PT148981731T patent/PT3173382T/pt unknown
- 2014-07-21 CN CN201480082106.9A patent/CN106715332B/zh active Active
- 2014-07-21 PL PL14898173.1T patent/PL3173382T3/pl unknown
- 2014-07-21 RS RS20230179A patent/RS64025B1/sr unknown
- 2014-07-21 BR BR112017001287-1A patent/BR112017001287A2/pt not_active Application Discontinuation
- 2014-07-21 HU HUE14898173A patent/HUE061726T2/hu unknown
- 2014-07-21 HR HRP20230223TT patent/HRP20230223T1/hr unknown
- 2014-07-21 WO PCT/ES2014/070586 patent/WO2016012632A1/es active Application Filing
- 2014-07-21 JP JP2017502966A patent/JP6534439B2/ja active Active
- 2014-07-21 FI FIEP14898173.1T patent/FI3173382T3/fi active
- 2014-07-21 ES ES14898173T patent/ES2940465T3/es active Active
- 2014-07-21 DK DK14898173.1T patent/DK3173382T3/da active
- 2014-07-21 KR KR1020177004653A patent/KR102282865B1/ko active IP Right Grant
- 2014-07-21 AU AU2014401750A patent/AU2014401750B2/en active Active
- 2014-07-21 SG SG11201700485VA patent/SG11201700485VA/en unknown
- 2014-07-21 EP EP14898173.1A patent/EP3173382B1/en active Active
-
2015
- 2015-07-20 AR ARP150102288A patent/AR101252A1/es unknown
- 2015-07-20 UY UY0001036222A patent/UY36222A/es not_active Application Discontinuation
- 2015-07-21 TW TW104123580A patent/TWI709407B/zh active
-
2017
- 2017-01-22 IL IL250212A patent/IL250212B/en active IP Right Grant
- 2017-02-20 ZA ZA2017/01241A patent/ZA201701241B/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6045721B2 (ja) * | 2013-01-22 | 2016-12-14 | オキソライフ エセ.エレ. | 非糖尿病の哺乳動物における雌性不妊症の治療のためのタングステン(vi)塩の使用 |
Non-Patent Citations (2)
Title |
---|
HUMAN REPRODUCTION, vol. 22, no. 8, JPN6018002349, 2007, pages 2128 - 2135 * |
SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 27, no. 2, JPN6018038303, 2001, pages 20 - 2 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Langley-Evans | Nutrition: a lifespan approach | |
KR102376425B1 (ko) | 여성 가임능 촉진용 조성물 | |
WO2020262325A1 (ja) | 雌の抗老化剤 | |
Abadjieva et al. | Opportunities for the improvement of the reproductive performances in female animals | |
JP6534439B2 (ja) | 非糖尿病の雌性哺乳動物において生殖能力及び正常な妊孕力を刺激するための及び生殖補助医療の有効性を改善させるための、不妊症の治療に使用されるタングステン(vi)塩 | |
AU2015263221B2 (en) | Food compositions comprising tungsten (VI) salts | |
CN107412216A (zh) | α‑酮戊二酸在改善高脂饮食导致的动物繁殖功能损伤方面的应用 | |
NZ728467B2 (en) | Tungsten (vi) salts used to treat infertility, for stimulating fertility and normal reproduction in a non-diabetic female mammal, and for improving the effectiveness of assisted reproduction techniques | |
Aguillar-Gomes et al. | Toxic effects of glibenclamide in fetuses of normoglycemic rats: an alternative therapy for gestational diabetes mellitus | |
Ramella et al. | Effects of postpartum treatment with oral calcium formate on serum calcium, serum metabolites, and the occurrence of diseases at the beginning of lactation of high-producing dairy cows | |
US20240207366A1 (en) | Food composition and pharmaceutical composition for preventing or alleviating sarcopenia, containing low-molecular-weight collagen as active ingredient | |
ES2639588B1 (es) | Uso de una sal de tungsteno (VI) para favorecer la fertilidad y la reproducción normal en un mamífero hembra no diabético | |
KR101879975B1 (ko) | 나린제닌을 유효성분으로 포함하는 임신촉진용 조성물 | |
Mizgier et al. | The role of obesity and environmental factors such as diet and physical activity in the etiopathogenesis of fertility disorders | |
青木悠介 et al. | Effect of Lepidium meyenii on in vitro fertilization via improvement in acrosome reaction and motility of mouse and human sperm | |
KR101788299B1 (ko) | 프로토카테츄산을 유효성분으로 포함하는 임신 촉진용 조성물 | |
Karim et al. | Effect of Adding Calcium Propionate on Productive Performance of Iraqi Buffaloes | |
Stewart | Physiological consequences of exposure to heat stress and the mycotoxin zearalenone | |
Olabanji et al. | The Impact of Ethanolic Extract of Moringa oleifera Leaf on Foetal Development and Growth in Streptozotocin-Induced Diabetic Wistar Rat. | |
KR101669887B1 (ko) | 벤조인산을 유효성분으로 포함하는 임신 촉진용 조성물 | |
Otašević et al. | Impact of nutrition on human fertility | |
KR20190137393A (ko) | 올레산을 유효성분으로 포함하는 임신촉진용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170526 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180130 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180427 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20181002 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190104 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190514 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190528 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6534439 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |